Cipher Pharmaceuticals Reports Voting Results for the Election of Directors

Published: May 11, 2018

MISSISSAUGA, ON, May 11, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced today the voting results for the election of directors at its Annual and Special Meeting of Shareholders held on May 10, 2018 in Toronto, Ontario.

A total of 16,723,457 common shares representing 62.5% of the Company's issued and outstanding common shares were represented at the meeting. Shareholders voted in favour of all items of business put forth at the meeting. The votes for the election of directors are as follows:

    Nominee                % of Shares Voted For  % of Shares Voted Withhold

    Dr. John Mull                          98.56%                      1.44%

    Harold Wolkin                          98.74%                      1.26%

    Christian Godin                        98.25%                      1.75%

    Mark Beaudet                           99.07%                      0.93%

    Arthur Deboeck                         98.62%                      1.38%

    Robert Tessarolo                       98.65%                      1.35%

    Dr. Laurence Terrisse-
     Rulleau                               98.72%                      1.28%

 

About Cipher Pharmaceuticals Inc.

Cipher (TSX:CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. Cipher is focused on a three-pronged growth strategy - including acquisitions, in-licensing, and selective investments in drug development - to assemble a broad portfolio of prescription products that serve unmet medical needs. For more information, visit www.cipherpharma.com.

 

Craig Armitage, LodeRock Advisors, (416) 347-8954, craig.armitage@loderockadvisors.com

SOURCE Cipher Pharmaceuticals Inc.

Back to news